Scholar Rock Holding Corporation (SRRK)
| Previous close | 7.97 |
| Open | 7.29 |
| Bid | 6.65 x 1000 |
| Ask | 10.90 x 800 |
| Day's range | 7.80 - 7.84 |
| 52-week range | 4.32 - 36.43 |
| Volume | |
| Avg. volume | 421,492 |
| Market cap | 405.121M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.03 |
| Earnings date | 07 Nov 2022 - 11 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.71 |
- Business Wire
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
CAMBRIDGE, Mass., October 04, 2022--Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at WMS Congress and International Scientific Congress on Spinal Muscular Atrophy.
- Business Wire
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., September 22, 2022--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role today announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in September 2022. The award is subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Plan (the "Plan") and form of st
- Business Wire
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
CAMBRIDGE, Mass., September 20, 2022--Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
